Page 132 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $5.22
52wk Low $1.05 MAIA Biotechnology, Inc. MAIA $1.17
444 West Lake Street
Chicago, IL 60606

(USD - in millions) www.MAIABiotech.com
Market Cap 19.9
Enterprise 13.8
Basic Shares Out. 16.94 COMPANY OVERVIEW
Float 11.94
Institutional Holdings 1.85% Detailed Analysis:Channelchek.com
Short Interest 0.30
Avg. 90-Day Volume 0.31 MAIA is a targeted therapy, immuno-oncology company focused on the
development and commercialization of potential first-in-class drugs with
novel mechanisms of action that are intended to meaningfully improve
and extend the lives of people with cancer. Our lead program is THIO,
EPS Data a potential first-in-class cancer telomere targeting agent in clinical
development for the treatment of NSCLC patients with telomerase-
2021 2022 2023 positive cancer cells.
CQ1 N/A N/A (0.38)
CQ2 N/A N/A (0.35)

CQ3 N/A N/A (0.36)
CQ4 N/A N/A (0.40)
CY N/A (1.76) (1.51) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.20
ROE (ttm) -243.80
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
444 West Lake Chicago IL 60606

Key Executives
CEO: Vitoc, Vlad
CFO: McGuire, Joseph
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures